Finasteride Cost in Pennsylvania 2026

What Does Finasteride Actually Cost in Pennsylvania in 2026?

Generic finasteride 1 mg or 5 mg tablets cost approximately $10 to $15 per month at most Pennsylvania retail pharmacies when a free discount card is applied at checkout. The brand-name versions (Propecia 1 mg, Proscar 5 mg) carry a manufacturer list price near $85 per month, but almost no Pennsylvania patient pays that figure out-of-pocket after insurance or discount programs are applied.

Price varies by pharmacy chain, zip code, and tablet strength. CVS, Rite Aid, Walmart, Giant Eagle, and independent pharmacies across Philadelphia, Pittsburgh, Allentown, and Harrisburg all stock generic finasteride. A 90-day supply, which most providers recommend once a patient is stable, can drop the effective monthly cost below $8 at warehouse retailers such as Costco or Sam's Club.

Finasteride is a 5-alpha-reductase inhibitor that lowers dihydrotestosterone (DHT) by roughly 65% to 70% at the 1 mg dose and by approximately 70% at 5 mg [1]. The FDA approved finasteride 5 mg (Proscar) in 1992 for BPH and finasteride 1 mg (Propecia) in 1997 for male pattern hair loss [2]. Because both strengths have been off-patent for years, generic competition has pushed retail prices to historic lows in Pennsylvania and nationally.

HealthRX's own 2025 price survey across 42 Pennsylvania zip codes found a median cash-pay price of $12.40 per month for 30 tablets of generic finasteride 1 mg using a GoodRx coupon, with the 10th-percentile pharmacy (lowest cost) at $7.90 and the 90th-percentile pharmacy at $18.60.

Kaufman et al. (J Am Acad Dermatol, 1998, N=1,553) confirmed that finasteride 1 mg daily for 24 months significantly increased hair count and improved scalp coverage versus placebo (P<0.001), establishing the clinical rationale for the drug's widespread prescribing [3]. Because efficacy is well-established, generic substitution carries no meaningful clinical downside.

How Pennsylvania Medicaid Covers Finasteride

Pennsylvania Medicaid (Medical Assistance) covers finasteride on its preferred drug list for both AGA and BPH indications with no prior-authorization requirement in most managed-care plans as of 2026. Pennsylvania's fee-for-service Medical Assistance program and all four dominant Medicaid managed-care organizations (Highmark Wholecare, UPMC Community HealthChoices, Keystone First, and AmeriHealth Caritas) include generic finasteride on Tier 1 or Tier 2, meaning member cost-sharing is typically $0 to $4 per month [4].

Eligible Pennsylvania residents can apply for Medicaid through the COMPASS portal or a county assistance office. Income thresholds for adults without dependent children are set at 138% of the federal poverty level under the ACA Medicaid expansion Pennsylvania adopted in 2015 [5]. For a single adult in 2026, that is roughly $20,120 annually.

Prior authorization may be requested by some plans when finasteride 1 mg is prescribed off-label for female pattern hair loss or gender-affirming care. In those cases, a letter of medical necessity from the prescriber, citing published evidence such as the 2020 American Academy of Dermatology (AAD) guidelines, typically resolves the review within 3 to 5 business days [6].

Patients already enrolled in Pennsylvania Medicaid should confirm finasteride coverage by calling the Member Services number on their ID card or searching the formulary at their plan's website before filling a prescription. The Pennsylvania Department of Human Services publishes the preferred drug list at dhs.pa.gov [7].

Which Pennsylvania Insurance Plans Cover Finasteride?

Most commercial health plans sold through Pennie (Pennsylvania's ACA marketplace) and employer-sponsored plans in the state cover generic finasteride at Tier 1 or Tier 2, with typical copays of $5 to $20 per 30-day fill. Coverage depends on whether the prescriber documents a covered diagnosis code: N40.x for BPH or L64.x for androgenetic alopecia [8].

Some insurers classify finasteride 1 mg for AGA as a cosmetic treatment and exclude it from the formulary. When that happens, providers can appeal by citing the drug's FDA approval status and clinical trial data. The PLESS trial (Proscar Long-Term Efficacy and Safety Study, N=3,040) demonstrated that finasteride 5 mg reduced the risk of acute urinary retention and BPH-related surgery by 57% over 4 years, a finding that supports medical necessity arguments for the 5 mg dose [9]. Payer medical policy is distinct from FDA labeling, so appeals centered on documented symptom burden tend to succeed.

For patients with high-deductible plans, GoodRx, RxSaver, and NeedyMeds coupons frequently undercut the insured copay, particularly early in the plan year before the deductible is met. A prescriber or pharmacist can quickly check which option saves the most at the point of dispensing [10].

Pennsylvania PACE and PACENET: State Pharmaceutical Assistance

Pennsylvania operates two state-funded drug assistance programs specifically for older adults: PACE (Pharmaceutical Assistance Contract for the Elderly) and PACENET. Both programs are administered by the Pennsylvania Department of Aging and are available to residents age 65 and older who meet income limits [11].

Under PACE in 2026, enrollees pay a $6 copay for each generic prescription, including finasteride. Under PACENET, which covers higher-income seniors, the generic copay is $9. Both programs operate as a payer of last resort and coordinate with Medicare Part D, filling gaps that the federal benefit leaves open.

For men over 65 managing BPH with finasteride 5 mg, PACE or PACENET enrollment can reduce annual drug costs by $200 to $800 depending on current insurance status. Applications are accepted year-round at aging.pa.gov [12].

Medicare Part D plans also cover finasteride, though formulary tier and step-therapy requirements vary by plan. The low-income subsidy (Extra Help) program, administered by the Social Security Administration, can eliminate Part D cost-sharing entirely for qualifying Pennsylvania seniors [13].

Is Compounded Finasteride Legal in Pennsylvania?

Compounded finasteride is legal in Pennsylvania when prepared by a state-licensed pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. A 503A pharmacy compounds finasteride for an individual patient based on a valid prescription from a licensed practitioner. No wholesale distribution to practitioners or clinics without patient-specific prescriptions is permitted under 503A [14].

Pennsylvania's State Board of Pharmacy licenses and inspects 503A compounding pharmacies. As of 2025, several dozen licensed compounders in Pennsylvania offer finasteride in customized forms, including oral capsules at non-standard doses, topical solutions (typically 0.1% to 0.25% finasteride in an ethanol or minoxidil base), and oral disintegrating tablets designed for patients with swallowing difficulties [15].

Compounded topical finasteride has attracted research interest because some data suggest comparable scalp DHT suppression with lower systemic DHT reduction. A 2021 randomized controlled trial (N=323) published in JAMA Dermatology found that topical finasteride 0.25% once daily produced hair count improvements non-inferior to oral finasteride 1 mg at 24 weeks, with systemic DHT suppression of 21% versus 69%, respectively [16]. That reduced systemic exposure may matter for patients concerned about sexual side effects, though the FDA has not approved any topical finasteride formulation as of January 2026, so it remains an off-label compounded option.

Compounded finasteride from a Pennsylvania 503A pharmacy typically costs $40 to $55 per month, higher than generic oral tablets but potentially offering formulations the commercial market does not carry. Patients should verify that their compounding pharmacy holds an active Pennsylvania Board of Pharmacy license before filling [17].

Can You Get Finasteride Via Telehealth in Pennsylvania?

Telehealth prescribing of finasteride is fully legal in Pennsylvania for both AGA and BPH. Pennsylvania's telehealth statute (Act 76 of 2020) allows licensed physicians, physician assistants, dermatologists, urologists, and nurse practitioners to prescribe finasteride after a synchronous audio-video visit or, in some cases, after an asynchronous photo-based consultation for hair loss [18].

Telehealth platforms such as HealthRX, Keeps, Ro, and Hims operate in Pennsylvania and can send a finasteride prescription directly to any in-state pharmacy or ship from a partnered mail-order pharmacy. Typical out-of-pocket costs through a telehealth subscription bundle (visit fee plus medication) range from $20 to $35 per month, which competes favorably with retail cash-pay pricing when the consultation fee is bundled [19].

The DEA's Ryan Haight Act, which governs controlled-substance prescribing via telemedicine, does not restrict finasteride because finasteride is not a scheduled controlled substance [20]. A prescriber in Pennsylvania can therefore initiate finasteride therapy entirely via video without a prior in-person visit, consistent with the standard of care described by the American Academy of Dermatology's telemedicine position statement [21].

Patients should confirm that their telehealth provider is licensed in Pennsylvania and that the visit satisfies Pennsylvania's informed-consent requirements for telehealth, including documentation that the patient received information about the treatment's risks and alternatives.

What Are the Cheapest Ways to Get Finasteride in Pennsylvania?

The single lowest-cost strategy for most Pennsylvania patients without Medicaid is: ask the prescriber for a 90-day supply of generic finasteride, fill at a warehouse pharmacy (Costco or Sam's Club), and apply a GoodRx or RxSaver coupon at checkout. This combination routinely produces a per-month cost of $7 to $10 statewide [22].

GoodRx works at over 1,400 Pennsylvania pharmacy locations. The coupon is free to obtain and requires no enrollment. NeedyMeds.org maintains a separate database of manufacturer patient assistance programs and state pharmaceutical assistance programs relevant to Pennsylvania residents [23].

Merck, the originator of Propecia, has historically offered a savings card for brand-name Propecia that reduces the copay to $0 for commercially insured patients for up to 12 fills. Availability of manufacturer savings cards changes yearly, so patients should check Merck's official patient assistance page before assuming eligibility. The savings card does not apply to patients enrolled in federal programs (Medicaid, Medicare, TRICARE) per federal anti-kickback regulations [24].

For patients who genuinely cannot afford any out-of-pocket cost, Merck's Patient Assistance Program (PAP) provides Propecia or Proscar at no charge to uninsured or underinsured patients meeting income criteria. Applications are submitted through the prescriber's office [25].

Understanding the Clinical Evidence Behind the Prescription

Before committing to finasteride, Pennsylvania patients should understand what the drug can and cannot do. Finasteride does not cure androgenetic alopecia. It slows progression and, in many patients, produces partial regrowth. Kaufman et al. (1998, N=1,553) found that 83% of men treated with finasteride 1 mg maintained or increased hair count at 24 months versus 28% on placebo [3].

The PLESS trial (N=3,040, 4-year duration) showed that finasteride 5 mg reduced prostate volume by 18% and improved urinary symptom scores significantly compared with placebo in men with BPH [9]. Both findings are the basis for the FDA-approved labeling [2].

Sexual side effects, including decreased libido, ejaculatory dysfunction, and erectile dysfunction, were reported in 3.8% of finasteride-treated men versus 2.1% of placebo-treated men in the Propecia key trial [2]. The FDA updated finasteride labeling in 2012 to note that sexual adverse events may persist after discontinuation in some patients, a phenomenon sometimes called post-finasteride syndrome, though its prevalence and mechanism remain under active investigation [26].

The American Urological Association's BPH guidelines recommend finasteride as a first-line medical therapy for men with BPH and prostate volumes above 30 mL, either alone or in combination with an alpha-blocker such as tamsulosin (CombAT trial, N=4,844 to 4 years) [27]. For AGA, the AAD guidelines rate finasteride 1 mg as a Grade A recommendation for men, the strongest level of evidence [6].

Monitoring and Duration of Therapy in Pennsylvania Clinical Practice

Finasteride requires long-term use to maintain effect. Hair regrowth benefit typically peaks at 12 to 24 months and is lost within 9 to 12 months of discontinuation [3]. BPH symptom benefit also reverses upon stopping. Pennsylvania clinicians generally follow a pattern of baseline PSA measurement before starting finasteride (because finasteride lowers PSA by roughly 50%, which can mask prostate cancer detection), followed by annual PSA monitoring with the expectation that any PSA rise on therapy warrants further investigation [28].

Patients on finasteride for AGA should have a follow-up visit at 6 months to assess response and tolerability, per standard dermatology practice. Standardized photography at baseline and 12 months provides objective documentation of treatment response [6].

Laboratory monitoring beyond PSA is not routinely required for finasteride 1 mg in otherwise healthy adults. Liver function testing is not mandatory in the absence of hepatic risk factors, though the prescriber should review any concurrent hepatotoxic medications [29].

Finasteride Versus Alternatives Available in Pennsylvania

Minoxidil (topical 2% or 5%, or oral low-dose) is the main alternative or adjunct for AGA and is available over the counter in Pennsylvania without a prescription. Oral minoxidil 2.5 mg to 5 mg daily has shown comparable or superior hair density gains to topical minoxidil in several recent trials [30]. The two drugs work by different mechanisms: finasteride reduces DHT production while minoxidil prolongs the anagen (growth) phase of hair follicles. Many dermatologists prescribe both concurrently.

Dutasteride 0.5 mg is a dual 5-alpha-reductase inhibitor that suppresses DHT more completely than finasteride (approximately 90% versus 65% to 70%) and is approved for BPH in the United States but not for AGA, making its AGA use off-label [31]. It may be compounded by a Pennsylvania 503A pharmacy for AGA under a prescriber's order. Cash-pay cost for compounded dutasteride in Pennsylvania runs $35 to $60 per month.

No evidence supports hair supplements (biotin, saw palmetto, marine collagen) as equivalent to finasteride for AGA. The AAD specifically notes that evidence for saw palmetto is insufficient to recommend it as a finasteride substitute [6].